Drug intelligence / Profile preview

Chaiqin Tonglin tablets

Development stage: Unknown
Lead developer: Yiling Pharmaceutical
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Chaiqin Tonglin tablets is a traditional Chinese medicine (TCM) formulation developed by Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine. It is intended for the treatment of acute lower urinary tract infections and the prevention of recurrence in women with recurrent urinary tract infections (rUTI). The drug is formulated to target specific TCM syndrome patterns associated with urinary tract inflammation and dysfunction. It is currently undergoing Phase II clinical evaluation in China to assess its safety, optimal dosage, and preliminary efficacy in reducing infection recurrence.

Other names: Chaiqin Tonglin Pian

Beyond the preview

Go deeper on Chaiqin Tonglin tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chaiqin Tonglin tablets.

Explore the full profile